Having spent the last several years advancing its potentially disease-modifying nitrated fatty acid cell signaling approach targeting inflammatory and fibrotic indications, privately held Complexa Inc. is gearing up for phase II proof-of-concept trials after closing a $62 million series C round, by far its most substantial fundraising to date.